ASLAN PHARMACEUT. ADR/5 WKN: A2JN62 ISIN: US04522R1014 Forum: Aktien Thema: Hauptdiskussion

WL! 👍

Anticipated upcoming milestones Topline global pivotal trial (TreeTopp) data on varlitinib as second *** treatment for biliary tract cancer in mid-late November 2019. If positive, ASLAN intends to submit an NDA to the US FDA for accelerated approval in second-*** biliary tract cancer. Interim safety and efficacy data from a multiple ascending dose trial for ASLAN004 in patients with moderate to severe atopic dermatitis in early 2020. http://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-reports-third-quarter-2019-financial

ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second *** Biliary Tract Cancer at CSCO https://www.globenewswire.com/news-release/2019/09/19/1917777/0/en/ASLAN-Pharmaceuticals-Presents-Late-Breaking-Data-From-Phase-2-Study-in-China-Testing-Varlitinib-in-Second-***-Biliary-Tract-Cancer-at-CSCO.html

Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019 https://finance.yahoo.com/news/abstract-aslan-pharmaceuticals-varlitinib-accepted-091444219.html

New Data From Aslans Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting https://www.financialbuzz.com/new-data-from-aslans-study-of-varlitinib-in-china-accepted-as-late-breaking-oral-presentation-at-2019-csco-annual-meeting/

Sehr cool, vielen Dank für die Infos. Das schau ich mir doch mal genauer an

Wer suchet der findet.... Es gibt Marketscreener bei denen man über die Parameter die Auswahl eingrenzen kann und daneben gibt es für viele Branchen spezielle Ratgeberseiten. Für Biotechs zum Beispiel: biopharmcatalyst.com Für Aslan ist noch anzumerken, das wohl noch eine Kapitalerhöhung anstehen wird. Ich gehe nicht davon aus das sie mit ihren 15 Mio $ lange auskommen werden.

Wie kommst du denn auf sowas? Klingt sehr interessant

Schorsch du bist ja ein richtiger Wühler

ASLAN Partners BioGenetics To Commercialize Varlitinib ASLAN Pharmaceuticals will focus on clinical development of varlitinib while BioGenetics will obtain the necessary regulatory approvals for the use of the drug in South Korea. ASLAN will grant BioGenetics exclusive rights to commercialize varlitinib in South Korea in exchange for an upfront payment of US$2 million and up to US$11 million in sales and development milestones. ASLAN is also eligible to receive tiered double-digit royalties on net sales up to the mid-twenties. https://www.asianscientist.com/2019/03/pharma/aslan-biogenetics-varltinib-biliarty-tract-cancer/

Aslan Pharmaceuticals: An Asia-Focused Oncology Company Summary ASLN reported positive results from its biliary tract cancer trial. The company is focused on treating cancers that are common in Asian populations. This makes its investment thesis interesting for US investors. https://seekingalpha.com/article/4252763-aslan-pharmaceuticals-asia-focused-oncology-company

Anticipated upcoming milestones Presentation of new phase 1 data for varlitinib in combination with mFOLFIRI chemotherapy in advanced solid tumours at the European Society for Medical Oncology (ESMO) Congress 2019 in late September.   Initiation of a multiple ascending dose trial for ASLAN004 in patients with moderate to severe atopic dermatitis in the second half of 2019. Topline global pivotal trial (TreeTopp) data on varlitinib as second *** treatment for biliary tract cancer in the fourth quarter of 2019.

ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update https://finance.yahoo.com/news/aslan-pharmaceuticals-reports-second-quarter-080320228.html?.tsrc=rss&guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuYmlvcGhhcm1jYXRhbHlzdC5jb20vY29tcGFueS9BU0xO&guce_referrer_sig=AQAAADf944JPk4MfJUxQ3IvvyVqVMqSBzearpUc6aZvbzuCGOfTP6dH99OG4TRy3_Daotmp80BprONc49PPC41Rifw1ZeAOveh6fsjTfET9qQsds_iBrJ3AXmJidFSvPY5CPtexyH12rQ-VwL2jE2Qy1XAW5Kgs6xiCs6SaA0i0WNavY